Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...